Swiss National Bank Adverum Biotechnologies, Inc. Transaction History

Swiss National Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$1.74 - $2.4 $232,638 - $320,880	-133,700 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$9.26 - $14.36 $42,596 - $66,056	4,600 Added 3.56%	133,700 $1.32 Million
Q4 2020 Feb 05, 2021	SELL	$9.84 - $14.26 $104,304 - $151,156	-10,600 Reduced 7.59%	129,100 $1.4 Million
Q3 2020 Nov 09, 2020	BUY	$10.3 - $21.64 $58,710 - $123,348	5,700 Added 4.25%	139,700 $1.44 Million
Q2 2020 Aug 05, 2020	BUY	$8.53 - $25.64 $162,070 - $487,160	19,000 Added 16.52%	134,000 $2.8 Million
Q1 2020 May 08, 2020	BUY	$7.98 - $16.32 $81,396 - $166,464	10,200 Added 9.73%	115,000 $1.12 Million
Q4 2019 Feb 06, 2020	BUY	$5.12 - $12.22 $536,576 - $1.28 Million	104,800 New	104,800 $1.21 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $720M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.